Track Kronos Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Kronos Bio, Inc. KRON · Stock Open Kronos Bio, Inc. in new tab

0.8800 USD
Add to portfolio
EPS
-1.07
P/B
0.67
ROE
-59.49
Beta
1.64
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-1.07
Book Value1.31
Price to Book0.67
Debt/Equity30.18
% Insiders24.265%
Growth
Revenue Growth-0.26%
Estimates
Forward P/E-0.64
Forward EPS-1.38

DCF Valuation

Tweak assumptions to recompute fair value for Kronos Bio, Inc. (KRON)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Kronos Bio, Inc. Logo Kronos Bio, Inc. Analysis (KRON)

United States Health Care Official Website Stock

Is Kronos Bio, Inc. a good investment? Kronos Bio, Inc. (KRON) is currently trading at 0.8800 USD.

Investor FAQ

Does Kronos Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Kronos Bio, Inc.?

Kronos Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. As of June 20, 2025, Kronos Bio, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Exchange Ticker
NMS (United States) KRON
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion